TenQ · Stock reportUpdated 2026-10-16

AbCellera Biologics (ABCL)

$3.6B market cap · TenQ Score 12/36

Discovers antibodies for drugmakers, and is now developing its own drug candidates.

$11.80close as of 2026-10-16
+102.1% over 1Y · 85.3 points ahead of the S&P 500
$1.82$5.31$8.80$12.29$15.78Oct '25Dec '25Mar '26May '26Aug '26Oct '26

“Can AbCellera advance ABCL635 toward Phase 3 while partner payments support the cost of its internal pipeline?”

Editorial note · updated 2026-10-08
The TenQ Radar

AbCellera Biologics in 36 checks

AbCellera Biologics on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.

VALUEGROWTHQUALITYFINANCIAL HEALTHSHAREHOLDERRETURNSTREND

The business itself is the question here: 12 of 36 checks passed.

The AbCellera Biologics story

What drives AbCellera Biologics, what its price assumes and what could change the story, written from its own filings.

  • Clinical progress. In August 2026, AbCellera reported that ABCL635 met its Phase 2 primary efficacy endpoints for reducing the frequency and severity of hot flashes associated with menopause.
  • Revenue remains uneven. Revenue fell to $4.1 million in the quarter to June 2026 from $17.1 million in the prior year quarter, while net loss increased to $55.4 million from $34.7 million.
  • Liquidity supports development. AbCellera reported over $675 million in available liquidity at June 2026, including over $565 million in total cash balances and marketable securities and $110 million in available government funding.

Read the AbCellera Biologics story

Advertisement
Latest earnings

AbCellera Biologics' latest earnings

Q2 '26 · quarter to 30 June 2026 · reported 5 August 2026 · Earnings release ↗

Revenue$4M-76%vs 2025-51%vs Q1
Earnings-$55M-$21Mvs 2025-$12Mvs Q1
What the release says

The earnings summary is free with an account.

Sign up free to read it

AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q

Earnings alerts

An email when AbCellera Biologics reports, with its results and highlights. Free with a watchlist account.

I

Value

●●●●●●0/6

Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.

-no history
54.7xown 5-year median 21.1x
-3.3%cash earned per $ of price
-whole-business multiple
Valuation history

Is ABCL's P/E, P/S or P/B high or low against its own past?

→At 54.7x sales, the market is paying +159% more than ABCL's own 5-year median of 21.1x. Expectations are elevated, so more has to go right to justify the price.

What this measures

What the market has paid for each dollar of earnings, sales or book value, every year, with today's multiple as the last point and the median drawn across.

What good looks like. There is no good level. What matters is the distance from the company's own history, and whether the business has changed enough to justify it.

If it rises or falls. A multiple above its own median means the market expects more than it used to, so more has to go right. Below the median means the opposite, and the question is whether the pessimism is deserved. A multiple can also fall because earnings rose, which is the good way.

Free cash flow yield

What is ABCL's free cash flow yield at today's price?

→Every dollar of market value currently buys -3.3% of annual free cash flow, less than its 5-year median of -6.3% - you are paying up for the same cash.

What this measures

Free cash flow divided by market value: the cash the business generates for every dollar you pay for it. The inverse of a price-to-cash multiple.

What good looks like. A yield at or above the company's own history, and one that compares well with what cash is worth elsewhere.

If it rises or falls. The yield rises when cash grows or the price falls, so a high yield is either a bargain or a warning about the cash continuing. Read it beside the cash conversion chart, which shows whether the cash is holding up.

What does “Value” actually mean?

Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.

How we scored it · 0 of 6 checks passed
✕Cheaper than its own history (sales - not yet profitable)54.67 vs 21.11
✕Cheap on sales (under 2.5x)54.67 vs 2.50 (fixed yardstick)
✕Cheap on enterprise value vs sales (under 3x)52.86 vs 3.00 (fixed yardstick)
✕Free cash flow yield above 3%FCF yield -3.3%
✕Cheap on enterprise value (under 14x EBITDA)no EBITDA to value: -$204M over the last twelve months
✕Priced for less growth than its record suggestsnot profitable: no free cash flow or earnings for the price to rest on
II

Growth

●●●●●●2/6

Growth is weak or inconsistent. The trend, not the story, is the problem.

+101.3%vs the year before
-46.3%compound annual
-net income growth
-compound annual
Revenue history

Is ABCL's revenue growing?

◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)

→Revenue reached $75M in 2025, compounding -46% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $66M, behind the last full year.

What this measures

The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.

What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.

If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.

Revenue by productInsight

Where does AbCellera Biologics' revenue come from?

This insight is free with an account.

Sign up free to see it

→Research Fees is AbCellera Biologics' larger product line at $4M, 96% of $4M in 2026Q2, against $149,000 for Licensing and Royalty Revenue.

Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30

Profit history

Is ABCL's net profit growing?

◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)

→The company lost $146M in 2025, less than the $163M it lost the year before. The losses are narrowing, but it is still burning shareholder money.

What this measures

What is left after every cost, including tax and interest. The bottom line of the income statement.

What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.

If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.

Growth rate

How fast are ABCL's revenue and earnings growing?

→Revenue grew 101% over the twelve months to 2026-06-30, against an average of +27% a year over 2021-2025.

What this measures

How much revenue and earnings changed against the year before - the trailing twelve months against the twelve before them at each quarter, or one point per fiscal year. It is the speed of the business, not its size.

What good looks like. The earnings line above the revenue line: profits growing faster than sales means each new dollar of sales arrives more profitably than the last.

If it rises or falls. A high growth rate off a small base is easy and gets harder every year, so slowing growth in a large business is normal rather than a warning. Earnings falling while revenue grows is the combination worth understanding: costs are rising faster than sales.

Per-share growth

Are ABCL's revenue and free cash flow per share growing?

→Revenue per share reached $0.25 in 2025, compounding -45% a year - in line with ABCL's own -46%, so the share count is not distorting your slice. The trailing twelve months are running at $0.22 a share. Free cash flow per share stands at $-0.58.

What this measures

Revenue and free cash flow, each divided by the number of shares in issue and adjusted for splits so old and new years compare honestly. Both lines rising means each share owns more of the business's sales and cash.

What good looks like. Both lines rising, and revenue per share growing at least as fast as the company's total revenue, which the answer compares. Faster means buybacks are working for you; slower means new shares are absorbing part of the growth.

If it rises or falls. This is the line that actually reaches you. A company can grow revenue every year and still shrink your slice by issuing shares faster than it grows.

What does “Growth” actually mean?

Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).

How we scored it · 2 of 6 checks passed
✓Outgrew its sector over the last twelve months101.3% vs 20.4% (sector 70th pct, n=256)
✕Sustained growth beats its sector (3 years)-46.3% vs 18.5% (sector 70th pct, n=251)
✕Profits grew over the last twelve monthsloss-making: TTM net income -$165M
✕Profit growth beats its peers (3 years)loss-making: TTM net income -$165M
✓Growth is speeding up, not slowinglast twelve months 101.3% vs three-year pace -46.3%
✕Grew per share, not just in total-83.7% vs 0.0%
III

Quality

●●●●●●0/6

Profitability is thin or negative. The growth isn't turning into money yet.

-kept after direct costs
-340.2%kept after running costs
-17.3%profit on shareholders' money
-17.9%against a 10% cost of capital
-operating cash ÷ net income
Margins

What profit margin does ABCL keep on each sale?

→Operating margin compressed 334 points to -289% since 2022. The bottom line is still negative: costs below the operating line eat what is left. ABCL doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.

What this measures

What survives at three points on the way down the income statement: after the direct cost of the product, after the cost of running the company, and after everything.

What good looks like. Margins that hold or widen as the business grows. The level itself varies enormously by industry, so the shape over time tells you more than the number.

If it rises or falls. A widening margin means pricing power or costs under control. A compressing one means the opposite, and it compounds: on large revenue, two points of margin is a great deal of profit.

Earnings quality

Does ABCL's operating cash flow keep up with its profit?

→The company generated -$131M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.

What this measures

Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.

What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.

If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.

Returns on capital

What return on equity and on capital does ABCL earn?

→ROE of -17% and ROCE of -18% sit close together, so the returns come from the business itself rather than from borrowing.

What this measures

Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).

What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.

If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.

Cash conversion

How much of each sale does ABCL turn into free cash flow?

→Free cash flow is negative, so no share of revenue is currently converting to spare cash. Every sales dollar is being reinvested or consumed.

What this measures

Free cash flow as a share of revenue: how much of each dollar of sales survives both costs and capital spending.

What good looks like. A steady or rising share. Asset-light businesses convert far more than manufacturers, so compare a company with itself.

If it rises or falls. Falling conversion while revenue grows means growth is being bought with capital spending or working capital, which is fine while it lasts and painful when it stops.

Spending intensity

How much of its revenue does ABCL spend on capex, R&D and stock pay?

→The biggest claim on each sales dollar is research and development, at 249% of revenue (stock compensation 74%, capital spending 57%). That share has risen since 2022, so the cost of competing is climbing.

What this measures

Capital spending, research and development, and stock compensation, each as a share of revenue. The three ways a business pays to keep its position.

What good looks like. A share that is stable or falling while revenue grows, which means the cost of competing is not rising with the business.

If it rises or falls. Rising intensity means each new dollar of sales is getting more expensive to win. Falling intensity can mean efficiency, or it can mean under-investment that shows up years later.

Return on capital employed

Is ABCL's return on capital above what its capital costs?

→ABCL's return on capital is negative at -16.8% in 2025. The capital in the business is not yet earning anything back.

What this measures

The same return as the card above, but every filed year, against a 10% line that stands in for what capital costs.

What good looks like. Years above the line, and a trend that is flat or rising rather than drifting down towards it.

If it rises or falls. A business earning above its cost of capital creates value by growing; one earning below it destroys value by growing. The 10% line is a convention, not a law, so read the distance from it rather than the crossing.

What does “Quality” actually mean?

Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.

How we scored it · 0 of 6 checks passed
✕Better net margins than its sector-248.8% vs 8.2% (sector 70th pct, n=271)
✕Runs leaner than its sector (operating margin)-340.2% vs 10.5% (sector 70th pct, n=252)
✕Actually profitableTTM net income -$165M
✕Earns well on shareholders' money-17.3% vs 8.8% (sector 70th pct, n=249)
✕Earns a real return on the capital it employs-17.9% vs 10.0%
✕Generates cash despite the lossTTM operating cash flow -$95M on a net loss of $165M
IV

Financial health

●●●●●●4/6

Financially sound overall, with one or two things worth watching.

0.00xborrowed vs owned
12.8xnear-term bills coverage
-earnings ÷ interest bill
$120Mcash plus short-term investments
Debt & cash

How much debt does ABCL carry, and do its profits cover the interest?

→The company holds $120M in cash against $0.00 of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.

What this measures

Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.

What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.

If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.

Near-term liquidity

Do ABCL's current assets cover the bills due within a year?

→Near-term liquidity is comfortable: 12.8x of current assets for every dollar due within the year. That is stronger than in 2020.

What this measures

Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.

What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.

If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.

Cash conversion

How much of ABCL's revenue arrives as operating cash?

→ABCL's operations consumed cash rather than produced it over the last twelve months. Down from 23.2% in 2019.

What this measures

Operating cash flow as a share of revenue: of every dollar sold, how much reached the bank before capital spending.

What good looks like. A high share, holding up or improving. It is the clearest sign that reported profit is real.

If it rises or falls. It falls when customers take longer to pay or stock builds up, and it can stay high while profit falls - which is usually the more reassuring of the two.

Shareholders' equity

Is ABCL's shareholder equity (book value) growing?

→The company's own capital shrank from $1.2B in 2023 to $896M (-22%). Buybacks or losses are drawing the buffer down - the distinction matters.

What this measures

What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.

What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.

If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.

What does “Health” actually mean?

Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.

How we scored it · 4 of 6 checks passed
✓Comfortable near-term liquidity12.77 vs 1.50
✓Debt isn't dominating0.00 vs 1.00
✓Debt trending the right waydebt/equity 0.00 now vs 0.00 five years ago
✓Earnings cover the interestno debt
✕Converts sales to cash better than its sector-143.5% vs 14.4% (sector 70th pct, n=274)
✕Self-funding1.00 years of cash at current burn
V

Shareholder returns

●●●●●●1/6

ABCL returns nothing to shareholders yet. Every dollar stays in the business.

-bought back, TTM, over market value
-at the current rate
-dividends plus buybacks
$51Mlast 12m, dilutes the buybacks
+99.2%since 2019 (split-adjusted)
Share count change (split-adjusted)

Is ABCL's share count rising or falling?

→The share count grew 1.5% in 2025. Your slice of the company shrinks by that much each year unless earnings grow faster.

What this measures

The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.

What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.

If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.

Dilution against what it bought

Has ABCL's revenue per share grown faster than its share count?

Change since 2019. The gap between the lines is what each share gained or lost. Share counts are split-adjusted weighted averages.

→ABCL issued 97% more shares from 2019 to 2025, but revenue per share still rose 228%. The dilution bought more growth than it cost existing holders.

What this measures

The share count and revenue per share over the same years, both indexed to 100 at the start, so the two lines can be compared directly.

What good looks like. The per-share line above the share-count line: whatever the company did with its shares, more business ended up behind each one.

If it rises or falls. Issuing shares is not automatically bad. It is bad when the money raised buys less growth than the dilution cost, which is exactly what the gap between these two lines shows.

Why compare buybacks with stock compensation?

A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.

How we scored it · 1 of 6 checks passed
✓Share count isn't climbingshares down 5.1% over 3 years
✕Buybacks outpace the stock issued to staffno buybacks against $51M of stock compensation
✕Hands cash back to ownersno dividends and no buybacks in the last twelve months
✕Meaningful yield to owners (dividends and buybacks)0.00 returned, 0.0% of market value
✕Buybacks are sustained, not one-offpays no dividend and reports no buybacks
✕Buybacks growingpays no dividend and reports no buybacks
VI

Trend

●●●●●●5/6

A confirmed uptrend: above the cloud, above both trend lines, and the readings agree.

+83.3%the long-term trend line
+103.4%S&P 500 (SPY): +3.1%
+93.4%S&P 500 (SPY): +16.0%
-20.4%drawdown from peak
Trend

Which way is ABCL's share price trending?

Price chart loads as you scroll…

Chart by TradingView

→ABCL is in a clear uptrend: the price is above the cloud where recent trading settled, and that cloud is still rising underneath it. The last two weeks and the month-ago comparison both point up, so the shorter readings back the trend.

How the trend above is worked out

The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.

How we scored it · 5 of 6 checks passed
✓Price above the Kumo cloud$11.80 against a cloud top of $10.24
✕Price above the Tenkan and the Kijun$11.80 against the Tenkan (9 sessions) at $13.11 and the Kijun (26) at $12.67
✓Tenkan above the KijunTenkan $13.11 above the Kijun $12.67, 17 sessions since they crossed
✓The Senkou cloud ahead is risingthe Senkou spans already drawn for the next 26 sessions are rising
✓Chikou above the price 26 sessions back$11.80 against $10.46 26 sessions ago
✓Beating the S&P 500 over 12 months93.4% vs 16.0%
VII

Insider activity

informational
$4Mtheir own money
$0.00often pre-scheduled
15of the last filings
11grants · exercises · tax
Open-market flow

Are ABCL's insiders buying or selling shares with their own money?

→Since November 2023, insiders bought $4M of stock on the open market and sold nothing. Buying with their own money is the one insider signal that is hard to explain away. A further 11 transactions were grants, option exercises or tax withholding, which say nothing either way.

What this measures

Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.

What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.

If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.

The record

Who did what, exactly?

DateInsiderRoleTypeSharesPriceValue
2026-08-24Michael R HaydenDirectorBUY53,613$10.64$570,442
2026-08-18John S. MontalbanoDirectorBUY10,000$11.03$110,300
2026-08-14Andrew BoothChief Financial OfficerBUY37,200$10.32$383,904
2026-08-12Michael R HaydenDirectorBUY46,387$10.37$481,033
2026-06-03Andrew BoothChief Financial Officerexercise250,000$0.19$47,500
2026-05-14John S. MontalbanoDirectorBUY20,000$4.77$95,400
2026-02-27Thermopylae Holdings Ltd.10% ownerBUY38,000$3.44$130,720
2026-02-27Andrew BoothChief Financial OfficerBUY42,600$3.42$145,692
2026-02-26Thermopylae Holdings Ltd.10% ownerBUY177,457$3.27$580,284
2025-11-26John S. MontalbanoDirectorBUY50,000$3.57$178,460
Why do the transaction types matter so much?

Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.

VIII

Ownership

informational
37.9%on Form 13F, 30 June 2026
38.5%officers, directors, founders
67.6%together
Top holders

Who owns AbCellera Biologics stock?

Fund managers filing Form 13F held 37.9% of the company's shares on 30 June 2026. The largest holder is Carl L. G. Hansen, with 18.6%. Insiders hold 38.5%.

#HolderStakeSharesValueChange
1Carl L. G. HansenChief Executive Officer · Form 4, 25 November 202418.59%57.0M$672M-
2Thermopylae Holdings Ltd.10% owner · Form 4, 27 February 202618.31%56.1M$662M-
3Baker Bros. Advisors LPFund manager10.77%33.0M$390M+9.0%

The full list of top holders is free with an account

Sign up free

Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.

Where does this list come from?

Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.

§

Recent filings

A short weekly note on what changed in the numbers, coming soon.One email a week: the charts that mattered, nothing else.
Where these numbers come from. Financial statements: US SEC EDGAR (XBRL company facts, as filed - including restatements; hatched chart bars are fourth quarters derived from annual filings), current to 2026-06-30. Prices: delayed end-of-day, as of 2026-10-16. Scores are counts of the transparent pass/fail checks shown in each chapter; every sentence on this page is computed from the data shown, except the labelled editorial note. Missing data is shown as missing, never estimated. Nothing here is investment advice. Terms · Methodology